NCT05451212 2025-11-10
Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis
Cabaletta Bio
Phase 1 Completed
Clinical Trials
9 trialsNCT05737160 2025-05-23
Study of Telitacicept in Generalized Myasthenia Gravis
RemeGen Co., Ltd.
Phase 3 Completed
NCT06035614 2023-09-13
Efficacy and Safety of 308-nm Excimer Lamp Combined With Tacrolimus vs Tacrolimus as Monotherapy in Treating Vitiligo on Children
Clarteis
Phase NA Completed
NCT03348046 2020-03-04
PASSRRA
Hikma Pharmaceuticals LLC
Completed
NCT01953822 2016-12-26
Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom
GlaxoSmithKline
Completed
NCT01498627 2015-04-06
PGRx
GlaxoSmithKline
Completed
NCT01153906 2014-12-02
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination
GlaxoSmithKline
Completed
NCT00731536 2013-10-16
Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands
Centocor Ortho Biotech Services, L.L.C.
Completed
NCT01210716 2013-09-23
Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device
Fenwal, Inc.
Phase 3 Completed